Oncaidia has, under licence and subject to successful protection of the intellectual property internationally, the exclusive worldwide rights to four important patent applications arising from discoveries made by medical scientists working at the Hanson Institute, Adelaide, South Australia. These inventions cover novel markers of cancer cell death.

The first three applications cover APOMAB®, the technology that is the primary focus of Oncaidia’s R&D efforts. APOMAB® is a product that targets dead and dying cancer cells and it offers a number of valuable applications.

“A Method of Diagnosis and Treatment”
Publication No. WO2004073739
Date of filing 23 January 2004

“A Method of Treatment and Agents Useful for Same”
Publication No WO2008043148
Date of filing 11 October 2007

“A Method of Diagnosis and Agents Useful for Same”
Publication No WO2008043153
Date of filing 11 October 2007

Oncaidia is preparing further patent applications relating to APOMAB®.

Oncaidia also has the rights to a further patent application covering another technology that may serve as a blood-based diagnostic test for cancer.

"A Method of Diagnosis and Treatment and Agents
Useful for Same”
Publication No WO2006102716
Date of filing 31 March 2006